Compare PI & MESO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Impinj Inc operates a platform that enables wireless connectivity to everyday items by delivering each item's identity, location, and authenticity to business and consumer applications. Its platform includes endpoint integrated circuits (ICs) product, a miniature radios-on-a-chip, which attach to and identify their host items; and connectivity layer that comprises readers, gateways, and reader ICs to wirelessly identify, locate, authenticate, and engage endpoints via RAIN, as well as provide power to and communicate bidirectionally with endpoint ICs. Geographically, the company has a business presence in the Americas, Asia Pacific, Europe, Middle East and Africa, of which key revenue is derived from the operations in the Asia Pacific region.
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.